UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

Clinical cancer research, 2020-12, Vol.26 (23), p.6284-6298

2020

Volltextzugriff (PDF)

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype

Cell reports (Cambridge), 2018-05, Vol.23 (5), p.1448-1460

2018

Volltextzugriff (PDF)

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Cancer immunology research, 2017-01, Vol.5 (1), p.29-41

2017

Volltextzugriff (PDF)

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

Cancer immunology research, 2015-09, Vol.3 (9), p.1052-1062

2015

Volltextzugriff (PDF)

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Journal for immunotherapy of cancer, 2019-09, Vol.7 (1), p.244-244, Article 244

2019

Volltextzugriff (PDF)

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer

The Journal of clinical investigation, 2017-03, Vol.127 (3), p.801-813

2017

Volltextzugriff (PDF)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade

Frontiers in immunology, 2018-06, Vol.9, p.1082-1082

2018

Volltextzugriff (PDF)

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

Journal for Immunotherapy of Cancer, 2014-08, Vol.2 (1), Article 29

2014

Volltextzugriff (PDF)

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

Oncoimmunology, 2022-12, Vol.11 (1), p.2117321-2117321

2022

Volltextzugriff (PDF)

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments

Frontiers in immunology, 2023-10, Vol.14, p.1258291-1258291

2023

Volltextzugriff (PDF)

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Clinical cancer research, 2007-06, Vol.13 (12), p.3682-3688

2007

Volltextzugriff (PDF)

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (7), p.1804-1813

2012

Volltextzugriff (PDF)

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Clinical cancer research, 2010-02, Vol.16 (4), p.1159-1169

2010

Volltextzugriff (PDF)

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity

Oncoimmunology, 2019-08, Vol.8 (8), p.1-10

2019

Volltextzugriff (PDF)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Journal for immunotherapy of cancer, 2017-08, Vol.5 (1), p.63-63, Article 63

2017

Volltextzugriff (PDF)

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Molecular oncology, 2009-06, Vol.3 (3), p.248-261

2009

Volltextzugriff (PDF)

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Molecular cancer therapeutics, 2009-07, Vol.8 (7), p.1856-1866

2009

Volltextzugriff (PDF)

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19), p.5458-5468

2014

Volltextzugriff (PDF)

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

Clinical cancer research, 2017-09, Vol.23 (18), p.5514-5526

2017

Volltextzugriff (PDF)

Statistically Integrated Metabonomic−Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice

Journal of proteome research, 2006-10, Vol.5 (10), p.2642-2655

2006

Volltextzugriff (PDF)

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (10), p.4150-4158

2009

Volltextzugriff (PDF)

Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression

SLAS discovery, 2022-03, Vol.27 (2), p.95-106

2022

Volltextzugriff (PDF)

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

Cancer Immunology, Immunotherapy, 2015-10, Vol.64 (10), p.1229-1239

2015

Volltextzugriff (PDF)

Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer

Clinical & translational immunology, 2020, Vol.9 (9), p.e1177-n/a

2020

Volltextzugriff (PDF)

1 – 25 von 696

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(621)
Mit Volltextzugriff
(583)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(447)
Life Sciences & Biomedicine
(372)
Humans
(294)
Male
(155)
Female
(148)
Animals
(132)
Biological And Medical Sciences
(115)
Medical Sciences
(90)
Adult
(84)
Middle Aged
(75)
Mice
(71)
Oncology
(65)
Aged
(57)
Physical Sciences
(43)
Science & Technology - Other Topics
(42)
Immunology
(41)
Multidisciplinary Sciences
(40)
Biochemistry & Molecular Biology
(38)
Surgery
(36)
Pharmacology. Drug Treatments
(34)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

Statistically Integrated Metabonomic−Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo

Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer

Suchergebnisse filtern